Cellular senescence molecules expression in type 2 diabetes mellitus: CDKN2A, CDKN2B, and lncRNA ANRIL

被引：1
|
作者：
Anaraki, Soheila [1 ]
Kheirandish, Masoumeh [2 ]
Mousavi, Pegah [3 ]
Tamandegani, Atefe Ebrahimi [1 ]
Mohammadi, Samane [1 ]
Shekari, Mohammad [1 ]
机构：
[1] Hormozgan Univ Med Sci, Fac Med, Dept Med Genet, Bandar Abbas 7919915519, Iran
[2] Hormozgan Univ Med Sci, Endocrinol & Metab Res Ctr, Bandar Abbas, Iran
[3] Hormozgan Univ Med Sci, Hormozgan Hlth Inst, Mol Med Res Ctr, Bandar Abbas, Iran
来源：
GENE | 2024年 / 911卷
关键词：
Biomarker; Long noncoding RNA; Cyclin-dependent kinase inhibitor 2A /2B; CDKN2B-AS1; Real-time PCR; Peripheral blood mononuclear cells; INFLAMMATION; DISEASE; CELLS;
D O I：
10.1016/j.gene.2024.148319
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Aims: Cellular senescence in type 2 diabetes mellitus (T2DM) has received widespread attention. However, the cellular senescence molecules involved in T2DM are unclear. Furthermore, there are no consistent biomarkers for cellular senescence in T2DM. Therefore, this study aimed to identify cellular senescence molecules in T2DM and investigate their expression in peripheral blood mononuclear cells of individuals with T2DM. Methods: Patients with T2DM (n = 40) and healthy controls (n = 40) were enrolled. We used different databases to identify cellular senescence molecules in T2DM and confirmed the obtained genes and lncRNA using real-time PCR. Results: Bioinformatics analysis indicated that CDKN2A and CDKN2B genes, and long noncoding RNA ANRIL are the most effective cellular senescence molecules in T2DM. Furthermore, CDKN2A and ANRIL expression decreased in individuals with T2DM. Conclusions: Cellular senescence may have a protective effect against T2DM. In addition, the cellular senescence molecules CDKN2A and ANRIL may be potential biomarkers of cellular senescence in T2DM.
引用
收藏
页数：7
相关论文
共 50 条
  • [31] Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas
    Ashutosh Kumar Arya
    Sanjay Kumar Bhadada
    Priyanka Singh
    Naresh Sachdeva
    Uma Nahar Saikia
    Divya Dahiya
    Arunanshu Behera
    Anil Bhansali
    Sudhaker D. Rao
    Scientific Reports, 7
  • [32] Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas
    Arya, Ashutosh Kumar
    Bhadada, Sanjay Kumar
    Singh, Priyanka
    Sachdeva, Naresh
    Saikia, Uma Nahar
    Dahiya, Divya
    Behera, Arunanshu
    Bhansali, Anil
    Rao, Sudhaker D.
    SCIENTIFIC REPORTS, 2017, 7
  • [33] Serial studies of methylation of CDKN2B and CDKN2A in relapsed acute promyelocytic leukaemia treated with arsenic trioxide
    Au, WY
    Fung, AT
    Ma, ES
    Chan, CH
    Wong, KF
    Chim, CS
    Liang, RH
    Kwong, YL
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (05) : 632 - 635
  • [34] Association of CDKN2A/CDKN2B Gene Polymorphisms with Increased Susceptibility to Intracranial Aneurysm in a Chinese Han Population
    Cui, Xiaopeng
    Xin, Wen-Qiang
    Wang, Bangyue
    Zhao, Yan
    Hou, Changkai
    Cai, Shifei
    Peng, Chao
    Wang, Zhen
    Li, Jian
    Huan, Linchun
    Chen, Lei
    Yang, Xinyu
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 1443 - 1449
  • [35] Changes in CDKN2A/2B expression associate with T-cell phenotype modulation in atherosclerosis and type 2 diabetes mellitus
    Vinue, Angela
    Martinez-Hervas, Sergio
    Herrero-Cervera, Andrea
    Sanchez-Garcia, Veronica
    Andres-Blasco, Irene
    Piqueras, Laura
    Jesus Sanz, Maria
    Tomas Real, Jose
    Ascaso, Juan F.
    Jane Burks, Deborah
    Gonzalez-Navarro, Herminia
    TRANSLATIONAL RESEARCH, 2019, 203 : 31 - 48
  • [36] PROMOTER HYPERMETHYLATION MEDIATED SUPPRESSION OF CYCLIN DEPENDENT KINASE INHIBITORS (CDKN2A AND CDKN2B) IN SPORADIC PARATHYROID TUMORS
    Arya, A.
    Singh, P.
    Bhadada, S.
    Saikia, U.
    Sachdeva, N.
    Dahiya, D.
    Behera, A.
    Bhansali, A.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S704 - S704
  • [37] Association of Myocardial Infarction with CDKN2B Antisense RNA 1 (CDKN2B-AS1) rs1333049 Polymorphism in Slovenian Subjects with Type 2 Diabetes Mellitus
    Tibaut, Miha
    Naji, Franjo
    Petrovic, Daniel
    GENES, 2022, 13 (03)
  • [38] APOL1, CDKN2A/CDKN2B, and HDAC9 polymorphisms and small vessel ischemic stroke
    Akinyemi, R.
    Tiwari, H. K.
    Arnett, D. K.
    Ovbiagele, B.
    Irvin, M. R.
    Wahab, K.
    Sarfo, F.
    Srinivasasainagendra, V.
    Adeoye, A.
    Perry, R. T.
    Akpalu, A.
    Jenkins, C.
    Arulogun, O.
    Gebregziabher, M.
    Owolabi, L.
    Obiako, R.
    Sanya, E.
    Komolafe, M.
    Fawale, M.
    Adebayo, P.
    Osaigbovo, G.
    Sunmonu, T.
    Olowoyo, P.
    Chukwuonye, I.
    Obiabo, Y.
    Onoja, A.
    Akinyemi, J.
    Ogbole, G.
    Melikam, S.
    Saulson, R.
    Owolabi, M.
    ACTA NEUROLOGICA SCANDINAVICA, 2018, 137 (01): : 133 - 141
  • [39] CDKN2A and CDKN2BAS expression levels in patients with atherosclerosis
    Cengiz, M.
    Arslan, C.
    Gode, S.
    Dagistanli, F. K.
    Arapi, B.
    Deser, S. B.
    Bayoglu, B.
    FEBS JOURNAL, 2013, 280 : 350 - 350
  • [40] Deficient CDKN2B Expression A Double Hit for PAD
    Hess, Daniel L.
    Annex, Brian H.
    CIRCULATION RESEARCH, 2016, 118 (02) : 190 - 192
12345